Log in

NASDAQ:AYTUAytu Bioscience Stock Price, Forecast & News

+0.06 (+4.12 %)
(As of 05/25/2020 04:00 PM ET)
Today's Range
Now: $1.52
50-Day Range
MA: $1.52
52-Week Range
Now: $1.52
Volume6.79 million shs
Average Volume19.63 million shs
Market Capitalization$182.19 million
P/E RatioN/A
Dividend YieldN/A
Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AYTU



Sales & Book Value

Annual Sales$7.32 million
Book Value$0.43 per share


Net Income$-27,130,000.00
Net Margins-172.62%


Market Cap$182.19 million
Next Earnings Date9/24/2020 (Estimated)
OptionableNot Optionable

Receive AYTU News and Ratings via Email

Sign-up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.

Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions

How has Aytu Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Aytu Bioscience's stock was trading at $1.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AYTU stock has increased by 12.2% and is now trading at $1.5150. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aytu Bioscience?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aytu Bioscience.

When is Aytu Bioscience's next earnings date?

Aytu Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, September 24th 2020. View our earnings forecast for Aytu Bioscience.

How were Aytu Bioscience's earnings last quarter?

Aytu Bioscience Inc (NASDAQ:AYTU) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. The company had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7 million. Aytu Bioscience had a negative return on equity of 107.69% and a negative net margin of 172.62%. View Aytu Bioscience's earnings history.

When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?

Aytu Bioscience shares reverse split before market open on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for AYTU?

1 Wall Street analysts have issued 1 year price objectives for Aytu Bioscience's stock. Their forecasts range from $4.75 to $5.00. On average, they anticipate Aytu Bioscience's stock price to reach $4.88 in the next twelve months. This suggests a possible upside of 221.8% from the stock's current price. View analysts' price targets for Aytu Bioscience.

Has Aytu Bioscience been receiving favorable news coverage?

Headlines about AYTU stock have been trending negative on Tuesday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aytu Bioscience earned a news impact score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAytu Bioscience.

Who are some of Aytu Bioscience's key competitors?

What other stocks do shareholders of Aytu Bioscience own?

Who are Aytu Bioscience's key executives?

Aytu Bioscience's management team includes the following people:
  • Mr. Joshua R. Disbrow, Chairman & CEO (Age 44)
  • Mr. David A. Green, CFO, Sec. & Treasurer (Age 56)
  • Mr. Jarrett T. Disbrow, Chief Operating Officer (Age 44)

What is Aytu Bioscience's stock symbol?

Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."

Who are Aytu Bioscience's major shareholders?

Aytu Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Searle & CO. (0.17%), Soleus Capital Management L.P. (0.15%), ETRADE Capital Management LLC (0.08%), BlackRock Inc. (0.03%), HCR Wealth Advisors (0.02%) and HighTower Advisors LLC (0.02%). Company insiders that own Aytu Bioscience stock include Armistice Capital Master Fund, David A Green and Joshua R Disbrow. View institutional ownership trends for Aytu Bioscience.

Which institutional investors are selling Aytu Bioscience stock?

AYTU stock was sold by a variety of institutional investors in the last quarter, including Searle & CO.. View insider buying and selling activity for Aytu Bioscience.

Which institutional investors are buying Aytu Bioscience stock?

AYTU stock was bought by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., ETRADE Capital Management LLC, HCR Wealth Advisors, HighTower Advisors LLC, and BlackRock Inc.. Company insiders that have bought Aytu Bioscience stock in the last two years include Armistice Capital Master Fund, and Joshua R Disbrow. View insider buying and selling activity for Aytu Bioscience.

How do I buy shares of Aytu Bioscience?

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aytu Bioscience's stock price today?

One share of AYTU stock can currently be purchased for approximately $1.52.

How big of a company is Aytu Bioscience?

Aytu Bioscience has a market capitalization of $182.19 million and generates $7.32 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. Aytu Bioscience employs 52 workers across the globe.

What is Aytu Bioscience's official website?

The official website for Aytu Bioscience is aytubio.com.

How can I contact Aytu Bioscience?

Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.